---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-005061"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:31:39.773493+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Revolution Medicines posts corporate presentation; no specific financial updates disclosed

## Summary
- Corporate presentation dated January 9, 2024, titled 'On Target to Outsmart Cancer' posted on IR website.
- Presentation outlines oncology pipeline strategy; no financial results, guidance, or material developments provided.
- No new clinical data or major corporate events were disclosed in the filing or accompanying exhibit.

## SEC filing metadata
- accession: 0001193125-24-005061
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312524005061/0001193125-24-005061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312524005061/d106383d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-005061
- JSON: https://secwatch.observer/filing/0001193125-24-005061.json
- Plain text: https://secwatch.observer/filing/0001193125-24-005061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.